Taeger, Johannes and Moser, Christian and Hellerbrand, Claus and Mycielska, Maria E. and Glockzin, Gabriel and Schlitt, Hans J. and Geissler, Edward K. and Stoeltzing, Oliver and Lang, Sven A. (2011) Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer. MOLECULAR CANCER THERAPEUTICS, 10 (11). pp. 2157-2167. ISSN 1535-7163,
Full text not available from this repository. (Request a copy)Abstract
Activation of receptor tyrosine kinases, such as fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and VEGF receptor (VEGFR), has been implicated in tumor progression and metastasis in human pancreatic cancer. In this study, we investigated the effects of TKI258, a tyrosine kinase inhibitor to FGFR, PDGFR, and VEGFR on pancreatic cancer cell lines (HPAF-II, BxPC-3, MiaPaCa2, and L3.6pl), endothelial cells, and vascular smooth muscle cells (VSMC). Results showed that treatment with TKI258 impaired activation of signaling intermediates in pancreatic cancer cells, endothelial cells, and VSMCs, even upon stimulation with FGF-1, FGF-2, VEGF-A, and PDGF-B. Furthermore, blockade of FGFR/PDGFR/VEGFR reduced survivin expression and improved activity of gemcitabine in MiaPaCa2 pancreatic cancer cells. In addition, motility of cancer cells, endothelial cells, and VSMCs was reduced upon treatment with TKI258. In vivo, therapy with TKI258 led to dose-dependent inhibition of subcutaneous (HPAF-II) and orthotopic (L3.6pl) tumor growth. Immunohistochemical analysis revealed effects on tumor cell proliferation [bromodeoxyuridine (BrdUrd)] and tumor vascularization (CD31). Moreover, lymph node metastases were significantly reduced in the orthotopic tumor model when treatment was initiated early with TKI258 (30 mg/kg/d). In established tumors, TKI258 (30 mg/kg/d) led to significant growth delay and improved survival in subcutaneous and orthotopic models, respectively. These data provide evidence that targeting FGFR/PDFGR/VEGFR with TKI258 may be effective in human pancreatic cancer and warrants further clinical evaluation. Mol Cancer Ther; 10(11); 2157-67. (C) 2011 AACR.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | NUDE-MOUSE MODEL; FACTOR RECEPTOR; HEPATOCELLULAR-CARCINOMA; KINASE INHIBITOR; XENOGRAFT MODELS; GASTRIC-CANCER; EXPRESSION; MIGRATION; OVEREXPRESSION; GEMCITABINE; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 27 May 2020 08:39 |
| Last Modified: | 27 May 2020 08:39 |
| URI: | https://pred.uni-regensburg.de/id/eprint/19893 |
Actions (login required)
 |
View Item |
